Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY3561774 in Adults With Mixed Dyslipidemia
jRCT2031220033Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of solbinsiran in combined dyslipidaemia, lipid metabolism disorder and hyperlipidemia (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline for Non-High Density Lipoprotein-Cholesterol (non-HDL-C). Started Jun 2022; status: active, not recruiting.
02
Drugs
solbinsiran
03
Conditions
combined dyslipidaemialipid metabolism disorderhyperlipidemia
Beyond the preview
Go deeper on jRCT2031220033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220033.